NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance
NeuroPace Inc (NPCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance Q3 2026 total revenue of $23.1 million, including $22.9 million in RNS revenue representing 1% growth Revises full year 2026 revenue guidance to $91 million to $92 million; focused on i
How this was made
The 30-second read
Why it matters
The guidance downgrade signals slower growth, likely prompting a sell‑off in the stock.
Market read
Primary earnings release with revised guidance for a small-cap biotech, relevant for traders tracking sector momentum.
What to watch
Potential upside from upcoming FDA submissions and real‑world evidence study could mitigate revenue concerns.
Background
NeuroPace filed a Form 8‑K reporting Q3 2026 financials and revising its FY2026 revenue guidance.
Ticker impact
NeuroPace disclosed Q3 2026 results and updated full-year revenue guidance to $91M-$92M, down from prior $99.5M-$101.5M.
potential downside as investors price in lower revenue outlook
Guidance revision is a primary disclosure that directly reduces expected revenue, a material catalyst for a small-cap medical device company.
Market effects
May weigh on other neurotechnology and epilepsy‑treatment stocks.
Limited to U.S. biotech/medical device investors.
Minimal global impact beyond sector peers.
Counterpoint
If the company can accelerate Remote Care adoption, the guidance cut may be temporary.
Key entities
- CompanyNeuroPace Inc.
Medical device maker focused on epilepsy treatment.
